Federal Circuit Affirms Invalidation of Purdue Pharma’s OxyContin Patents

May 20, 2016

Reading Time : 1 min

Beginning in 2011, Purdue Pharma and Grunenthal GmbH filed Hatch-Waxman lawsuits against Teva Pharmaceuticals, Amneal Pharmaceuticals, Epic Pharma and Mylan Pharmaceuticals in response to their Abbreviated New Drug Applications seeking Food and Drug Administration approval to market generic versions of OxyContin. 

After a three-week bench trial in the Teva case, the district court ruled that all of the asserted patent claims are invalid. The district court then entered orders of dismissal in the cases against Amneal, Epic and Mylan based on collateral estoppel. Purdue and Grunenthal appealed the final judgment in the Teva case and the dismissal orders in the Amneal, Epic and Mylan cases.

On appeal, the Federal Circuit affirmed the district court’s invalidity determinations. The Court of Appeals rejected Purdue’s argument that its discovery of the source of the toxic impurity minimized in its claimed drug product supported patentability because the solution did not depend on the source of the impurity. The Federal Circuit also affirmed the district court’s dismissal of the actions against Amneal, Epic and Mylan for collateral estoppel because Purdue did not present any persuasive reasons why the Teva invalidity ruling should not apply to the other cases.

The Federal Circuit denied Purdue’s petition for panel rehearing and rehearing en banc.

Purdue Pharma L.P. v. Epic Pharma, LLC, No. 14-1294 (Fed. Cir.).

Share This Insight

Previous Entries

IP Newsflash

July 22, 2026

The Court of Federal Claims recently denied the United States’ motion to dismiss a patent infringement suit related to production of a COVID-19 vaccine. The court held that it had jurisdiction because the plaintiff filed its claim there before it filed a parallel suit in a district court and because it adequately pleaded the government’s involvement.

...

Read More

IP Newsflash

July 13, 2026

In a precedential and sua sponte Director Review decision, USPTO Director Squires recently vacated three related institution decisions nearly six months after institution where a district court later found the challenged claims invalid. Because the fourteen-day deadline to request Director Review of the institution decisions had passed, the Director used this opportunity to formally extend the deadline in two ways. First, he extended the fourteen-day deadline under 37 C.F.R. § 42.75(c)(1) to thirty days, which “puts requests for Director Review of decisions to institute trial on equal footing to requests for Director Review of final decisions or decisions not to institute trial.” Second, he outlined certain “exceptional circumstances” that warrant a further extension of the deadline to account for changes in the case that “surface after the deadline.” In the case at hand, the Director found the district court’s invalidity finding to be such an “exceptional circumstance” and ultimately initiated review and vacated the institution decisions on that basis.

...

Read More

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.